We examined how adding Saccharomyces boulardii to conventional treatments could aid in eradicating certain gastric infections. Through a thorough search of databases over the past two decades, we focused on outcomes, including nausea and other side effects.
Our findings suggest that incorporating Saccharomyces boulardii significantly enhances eradication rates while also decreasing nausea and other gastrointestinal issues. This gives us hope for better treatment options in battling these prevalent gastric conditions.
Read More
Saccharomyces boulardii reduces nausea effectivelyThe effect of Saccharomyces boulardii supplementation on Helicobacter pylori eradication in children: a systematic review and meta-analysis of Randomized controlled trials.
High relevance in treatment effectiveness
We explored how Saccharomyces boulardii supplementation, when added to standard triple therapy (STT), can impact children’s nausea during H. pylori treatment. Analyzing data from 15 randomized controlled trials with over 2,000 participants, we found that S. boulardii significantly reduced nausea rates compared to STT alone—down to 12.7% from 21.3%.
Besides nausea, there were also lower occurrences of other gastrointestinal side effects. This suggests that S. boulardii not only aids in treating the infection but also makes the treatment process easier for kids.
Read More
S. boulardii helps reduce nauseaInvestigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial.
Low significance for nausea relief
We conducted a double-blind, placebo-controlled study to see how Saccharomyces boulardii might help in reducing nausea during Helicobacter pylori eradication therapy.
Our findings suggest that those taking S. boulardii experienced significantly fewer gastrointestinal symptoms, including nausea, when compared to the control group.
While S. boulardii showed promise in alleviating some treatment-related side effects, Lactobacillus reuteri did not have notable effects. Further research with larger sample sizes is recommended to deepen our understanding.
Read More
We examined the use of probiotics—specifically Saccharomyces boulardii—as a remedy for preventing antibiotic-associated diarrhea (AAD) in children. Our analysis included 23 studies with nearly 4,000 participants, and we found that probiotics significantly reduced AAD incidence from 19% in control groups to 8% in those receiving probiotics.
While this suggests that probiotics can be beneficial, the overall evidence quality was moderate. Importantly, no serious side effects were reported, making probiotics a safe option for many children, though caution is advised in those with pre-existing health conditions.
Read More
We aimed to find out if probiotics could help prevent antibiotic-associated diarrhea (AAD) in children. In our evaluation of 23 studies involving nearly 4,000 kids, we discovered that probiotics, especially Lactobacillus rhamnosus and Saccharomyces boulardii, significantly reduced the incidence of AAD compared to placebo or no treatment.
The results showed that only 8% of children taking probiotics experienced AAD, versus 19% in the control group. Importantly, no serious adverse events were linked to probiotic use, making it a safe option. However, we also emphasized the need for further research to explore other probiotic strains and ensure consistent results.
Read More